Shanghai Henlius-复宏汉霖(02696.HK)：HLX43联合HLX07及汉斯状®用于晚期实体瘤治疗的临床试验申请获国家药监局批准

复宏汉霖(02696.HK)：HLX43联合HLX07及汉斯状®用于晚期实体瘤治疗的临床试验申请获国家药监局批准

Shanghai Henlius(HK:02696) Ge Long Hui·2026-01-27 09:35

Core Viewpoint - The company, Junshi Biosciences (复宏汉霖), has received approval from the National Medical Products Administration (NMPA) for a clinical trial application involving HLX43, a PD-L1 targeted antibody-drug conjugate, in combination with HLX07 and Hansizhuang for the treatment of advanced solid tumors [1] Group 1 - The clinical trial will be conducted in China once conditions are met [1]

Shanghai Henlius-复宏汉霖(02696.HK)：HLX43联合HLX07及汉斯状®用于晚期实体瘤治疗的临床试验申请获国家药监局批准 - Reportify